CARING AMBASSADORS

Empowering People to be Ambassadors of their Own Health Since 1997.

HEPATITIS C PROGRAM


Monthly Pubmed Review

Monthly Pubmed Review of the Most Relevant Research on
Hepatitis C
Literature Review, February 2015

CLINICAL TRIALS, COHORT STUDIES, PILOT STUDIES

Virological outcomes and treatment algorithms utilisation in observational study of patients with chronic hepatitis C treated with boceprevir or telaprevir. Sterling RK1, Kuo A, Rustgi VK, et al. Aliment Pharmacol Ther. 2015 Jan 28. doi: 10.1111/apt.13095. [Epub ahead of print.

All-Oral 12-Week Treatment With Daclatasvir Plus Sofosbuvir in Patients With Hepatitis C Virus Genotype 3 Infection: ALLY-3 Phase 3 Study. Nelson DR1, Cooper JN, Lalezari JP, et al. Hepatology. 2015 Jan 23. doi: 10.1002/hep.27726. [Epub ahead of print]

Early virological assessment during telaprevir- or boceprevir-based triple therapy in hepatitis C cirrhotic patients who failed a previous interferon based regimen – The ANRS CO20-CUPIC study. Bailly F1, Virlogeux V2, Dufour C3, et al. Clin Res Hepatol Gastroenterol. 2015 Jan 27. pii: S2210-7401(15)00002-9. doi: 10.1016/j.clinre.2014.12.007. [Epub ahead of print]

Contribution of genes for killer cell immunoglobulin-like receptors (KIR) to the susceptibility to chronic hepatitis C virus infection and to viremia. Kuśnierczyk P1, Mozer-Lisewska I2, Zwolińska K3, et al. Hum Immunol. 2015 Jan 27. pii: S0198-8859(15)00021-X. doi: 10.1016/j.humimm.2015.01.020. [Epub ahead of print]

STARTVerso1: A randomized trial of faldaprevir plus pegylated interferon/ribavirin for chronic HCV genotype-1 infection. Ferenci P1, Asselah T2, Foster GR3, et al. J Hepatol. 2015 Jan 2. pii: S0168-8278(14)00953-2. doi: 10.1016/j.jhep.2014.12.024. [Epub ahead of print]

Quantification of fibrosis by collagen proportionate area predicts hepatic decompensation in hepatitis C cirrhosis. Calvaruso V1, Di Marco V, Bavetta MG, et al. Aliment Pharmacol Ther. 2015 Mar;41(5):477-86. doi: 10.1111/apt.13051. Epub 2015 Jan 11

All-Oral 12-Week Treatment With Daclatasvir Plus Sofosbuvir in Patients With Hepatitis C Virus Genotype 3 Infection: ALLY-3 Phase 3 Study. Nelson DR1, Cooper JN, Lalezari JP, et al. Hepatology. 2015 Jan 23. doi: 10.1002/hep.27726. [Epub ahead of print]

Early virological assessment during telaprevir- or boceprevir-based triple therapy in hepatitis C cirrhotic patients who failed a previous interferon based regimen – The ANRS CO20-CUPIC study. Bailly F1, Virlogeux V2, Dufour C, et al. Clin Res Hepatol Gastroenterol. 2015 Jan 27. pii: S2210-7401(15)00002-9. doi: 10.1016/j.clinre.2014.12.007. [Epub ahead of print]

Reliability of risk-based screening for hepatitis C virus infection among pregnant women in Egypt. El-Kamary SS1, Hashem M2, Saleh DA, et al. J Infect. 2015 Jan 23. pii: S0163-4453(15)00030-4. doi: 10.1016/j.jinf.2015.01.009. [Epub ahead of print]

The ARRIBA concept: adequate resorption of ribavirin. de Kanter CT1, Koning L, Berden FA, et al. Antivir Ther. 2015 Jan 19. doi: 10.3851/IMP2935. [Epub ahead of print]

Simeprevir and Sofosbuvir for Treatment of Chronic Hepatitis C Infection. Childs-Kean LM1, Hand EO2. Clin Ther. 2015 Jan 16. pii: S0149-2918(14)00870-4. doi: 10.1016/j.clinthera.2014.12.012. [Epub ahead of print]

Efficacy and safety of simeprevir with PegIFN/ribavirin in naïve or experienced patients infected with chronic HCV genotype 4. Moreno C1, Hezode C2, Marcellin P3, J Hepatol. 2015 Jan 14. pii: S0168-8278(15)00002-1. doi: 10.1016/j.jhep.2014.12.031. [Epub ahead of print]

Virological response after 6 week triple-drug regimens for hepatitis C: a proof-of-concept phase 2A cohort study. Kohli A1, Osinusi A2, Sims Z3, et al. Lancet. 2015 Jan 12. pii: S0140-6736(14)61228-9. doi: 10.1016/S0140-6736(14)61228-9. [Epub ahead of print]

Effects on anemia of drug adjustment in patients with chronic hepatitis C during telaprevir-combined therapy. Tamori A1, Kioka K2, Sakaguchi H3, et al. Ann Hepatol. 2015 Jan-Feb;14(1):28-35.

Quantification of fibrosis by collagen proportionate area predicts hepatic decompensation in hepatitis C cirrhosis. Calvaruso V1, Di Marco V, Bavetta MG, et al. Aliment Pharmacol Ther. 2015 Mar;41(5):477-86. doi: 10.1111/apt.13051. Epub 2015 Jan 11.

BASIC AND APPLIED SCIENCE, PRE-CLINICAL STUDIES

The intrahepatic T cell compartment does not normalize years after therapy-induced hepatitis C virus eradication. Spaan M, Claassen MA, Hou , et al. J Infect Dis. 2015 Jan 30. pii: jiv059. [Epub ahead of print]

Determination of the HCV protease inhibitor telaprevir in plasma and dried blood spot by liquid chromatography tandem mass spectrometry. Verweij-van Wissen CP1, de Graaff-Teulen MJ, de Kanter CT, Aarnoutse RE, Burger DM. Ther Drug Monit. 2015 Jan 26. [Epub ahead of print]

Indolamine 2,3-dioxygenase expression by monocytes and dendritic cell populations in hepatitis C patients. Schulz S1, Landi A, Garg R, Wilson J, van Drunen Littel-van den Hurk S. Clin Exp Immunol. 2015 Jan 20. doi: 10.1111/cei.12586. [Epub ahead of print]

Immune mechanisms of vaccine induced protection against chronic hepatitis C virus infection in chimpanzees. Verstrepen BE1, Boonstra A1, Koopman G1. World J Hepatol. 2015 Jan 27;7(1):53-69. doi: 10.4254/wjh.v7.i1.53.

Chronic hepatitis C virus infection triggers spontaneous differential expression of biosignatures associated with T cell exhaustion and apoptosis signaling in peripheral blood mononucleocytes. Barathan M1, Gopal K, Mohamed R, et al. Apoptosis. 2015 Jan 11. [Epub ahead of print]

Hepatitis C Virus Mediated Enhancement of miR-373 Impairs JAK/STAT Signaling Pathway. Mukherjee A1, Di Bisceglie AM2, Ray RB3. J Virol. 2015 Jan 14. pii: JVI.03085-14. [Epub ahead of print]

Vitamin D status and viral response to therapy in hepatitis C infected children. Eltayeb AA1, Abdou MA1, Abdel-Aal AM, et al. World J Gastroenterol. 2015 Jan 28;21(4):1284-91. doi: 10.3748/wjg.v21.i4.1284.

Clathrin mediates infectious hepatitis C virus particle egress. Benedicto I1, Gondar V1, Molina-Jiménez F, et al. J Virol. 2015 Jan 28. pii: JVI.03620-14. [Epub ahead of print]

Adiponectin serum level in chronic hepatitis C infection and therapeutic profile. Peta V1, Torti C1, Milic N, et al. World J Hepatol. 2015 Jan 27;7(1):44-52. doi: 10.4254/wjh.v7.i1.44.

Impaired induction of IL28B and expression of IFNλ4 associated with non-response to interferon-based therapy in chronic hepatitis C. Murakawa M1, Asahina Y, Nakagawa M, et al. J Gastroenterol Hepatol. 2015 Jan 22. doi: 10.1111/jgh.12902. [Epub ahead of print]

HIV/HCV COINFECTION

Hepatitis B virus and hepatitis C virus infection among HIV-1-infected injection drug users in Dali, China: prevalence and infection status in a cross-sectional study. Dong Y1, Qiu C, Xia X, et al.Arch Virol. 2015 Jan 24. [Epub ahead of print].

Sofosbuvir for chronic hepatitis C virus infection genotype 1-4 in patients co-infected with HIV. Rodriguez-Torres M1, Gaggar A, et al. J Acquir Immune Defic Syndr. 2015 Jan 23. [Epub ahead of print]

Therapy with boceprevir or telaprevir in HIV/hepatitis C virus co-infected patients to treat recurrence of hepatitis C virus infection after liver transplantation. Antonini TM1, Furlan V, Teicher E, et al. AIDS. 2015 Jan 2;29(1):53-8. doi: 10.1097/QAD.0000000000000516.

Sofosbuvir and Ribavirin for Treatment of Chronic Hepatitis C in Patients Co-infected with HIV: The Impact on Patient-Reported Outcomes. Younossi ZM1, Stepanova M1, Sulkowski M2, et al. J Infect Dis. 2015 Jan 12. pii: jiv005. [Epub ahead of print]

Multiple strategies are required to address the information and support needs of gay and bisexual men with hepatitis C in Australia. Hopwood M1, Lea T1, Aggleton P1. J Public Health (Oxf). 2015 Jan 26. pii: fdv002. [Epub ahead of print]

Sofosbuvir for chronic hepatitis C virus infection genotype 1-4 in patients co-infected with HIV. Rodriguez-Torres M1, Gaggar A, Shen G, et al. J Acquir Immune Defic Syndr. 2015 Jan 23. [Epub ahead of print]

STARTVerso4: faldaprevir and pegylated interferon α-2a/ribavirin in individuals co-infected with hepatitis C virus genotype-1 and HIV.  Dieterich D1, Nelson M, Soriano V, et al. AIDS. 2015 Jan 21. [Epub ahead of print]

STARTVerso4: faldaprevir and pegylated interferon α-2a/ribavirin in individuals co-infected with hepatitis C virus genotype-1 and HIV. Dieterich D1, Nelson M, Soriano V, et al. AIDS. 2015 Jan 21. [Epub ahead of print]

Persistently elevated abnormal B-cell subpopulations and anti-core antibodies in patients co-infected with HIV/HCV who relapse. Kohli A1, Funk E, Burbelo P, et al. J Med Virol. 2015 Jan 21. doi: 10.1002/jmv.24089. [Epub ahead of print]

Claudin-1 gene variants and susceptibility to hepatitis C infection in HIV-1 infected intravenous drug users (an ANRS case-control study). Ghosn J1, Fouquet B, Quertainmont Y, et al. J Med Virol. 2015 Jan 21. doi: 10.1002/jmv.24088. [Epub ahead of print]

 

COMPLEMENTARY AND ALTERNATIVE MEDICINE

Natural compounds isolated from Brazilian plants are potent inhibitors of hepatitis C virus replication in vitro. Jardim AC1, Igloi Z2, Shimizu JF3, et al. Antiviral Res. 2014 Dec 31. pii: S0166-3542(14)00369-6. doi: 10.1016/j.antiviral.2014.12.018. [Epub ahead of print]

Supercritical fluid extraction of heather (Calluna vulgaris) and evaluation of anti-hepatitis C virus activity of the extracts. García-Risco MR1, Vázquez E1, Sheldon J2, et al. Virus Res. 2014 Dec 27. pii: S0168-1702(14)00536-X. doi: 10.1016/j.virusres.2014.12.022. [Epub ahead of print]

EPIDEMIOLOGY, DIAGNOSTICS, AND MISCELLANEOUS WORKS

Long-term follow-up of successful hepatitis C virus therapy: waning immune responses and disappearance of liver disease are consistent with cure. Hedenstierna M1, Weiland O, Brass A, et al. Aliment Pharmacol Ther. 2015 Jan 28. doi: disease.10.1111/apt.13096. [Epub ahead of print]

Neuroimaging abnormalities, neurocognitive function, and fatigue in patients with hepatitis C. Thames AD1, Castellon SA1, Singer EJ1, et al. Neurol Neuroimmunol Neuroinflamm. 2015 Jan 14;2(1):e59. doi: 10.1212/NXI.0000000000000059. eCollection 2015.

Healthcare Worker Adherence to Follow-up After Occupational Exposure to Blood and Body Fluids at a Teaching Hospital in Brazil. Escudero DV, Furtado GH, Medeiros EA. Ann Occup Hyg. 2015 Jan 30. pii: meu117. [Epub ahead of print]

Polymorphisms in melanoma differentiation-associated gene 5 link protein function to clearance of hepatitis C virus. Hoffmann FS1, Schmidt A, Dittmann Chevillotte M, et al. Hepatology. 2015 Feb;61(2):460-70. doi: 10.1002/hep.27344. Epub 2015 Jan 5.

Donor Hepatitis C Sero-Status does not Impact Survival in Liver Transplantation. Montenovo MI1, Dick AA2, Hansen RN. Ann Transplant. 2015 Jan 22;20:44-50. doi: 10.12659/AOT.892530.

Bioengineering and Semisynthesis of an Optimized Cyclophilin Inhibitor for Treatment of Chronic Viral Infection. Hansson MJ1, Moss SJ2, Bobardt M, et al. Chem Biol. 2015 Jan 21. pii: S1074-5521(14)00454-2. doi: 10.1016/j.chembiol.2014.10.023. [Epub ahead of print]

Hepatitis C virus infection: a risk factor for Parkinson’s disease. Wu WY1, Kang KH, Chen SL, et al. J Viral Hepat. 2015 Jan 21. doi: 10.1111/jvh.12392. [Epub ahead of print]

Cost-effectiveness of screening for hepatitis C in Canada. Wong WW1, Tu HA1, Feld JJ1, Wong T1, Krahn M1. CMAJ. 2015 Jan 12. pii: cmaj.140711. [Epub ahead of print]

Virological outcomes and treatment algorithms utilisation in observational study of patients with chronic hepatitis C treated with boceprevir or telaprevir. Sterling RK1, Kuo A, Rustgi VK, et al. Aliment Pharmacol Ther. 2015 Jan 28. doi: 10.1111/apt.13095. [Epub ahead of print]

Vitamin D status and viral response to therapy in hepatitis C infected children. Eltayeb AA1, Abdou MA1, Abdel-Aal AM1, Othman MH1. World J Gastroenterol. 2015 Jan 28;21(4):1284-91. doi: 10.3748/wjg.v21.i4.1284.

LIVER CANCER

Cyclic adenosine monophosphate response element-binding protein transcriptionally regulates CHCHD2 associated with the molecular pathogenesis of hepatocellular carcinoma. Song R1, Yang B2, Gao X, et al. Mol Med Rep. 2015 Jan 26. doi: 10.3892/mmr.2015.3256. [Epub ahead of print]

HCV genotype 3 and squamous cell carcinoma antigen (SCCA)-IgM are independently associated with histological features of NASH in HCV-infected patients. Martini A1, Fattovich G, Guido M, et al. J Viral Hepat. 2015 Jan 22. doi: 10.1111/jvh.12394. [Epub ahead of print]

Surgical approach for hepatitis C virus-related hepatocellular carcinoma. Shindoh J1, Hashimoto M1, Watanabe G1. World J Hepatol. 2015 Jan 27;7(1):70-7. doi: 10.4254/wjh.v7.i1.70.

Utility of the FIB-4 Index for hepatocarcinogenesis in hepatitis C virus carriers with normal alanine aminotransferase levels. Ito T1, Kumada T, Toyoda H, et al. J Viral Hepat. 2015 Jan 21. doi: 10.1111/jvh.12389. [Epub ahead of print]

Drug interactions with new hepatitis C oral drugs. Soriano V1, Labarga P, Barreiro P, et al. Expert Opin Drug Metab Toxicol. 2015 Jan 2:1-9. [Epub ahead of print]

Hepatitis C Virus Antibody Prevalence, Demographics and Associated Factors among Persons Screened at Hawai’i Community-based Health Settings, 2010-2013. Takeuchi LC1, Pham TK1, Katz AR1. Hawaii J Med Public Health. 2015 Jan;74(1):9-15.

Surgical approach for hepatitis C virus-related hepatocellular carcinoma. Shindoh J1, Hashimoto M1, Watanabe G1. World J Hepatol. 2015 Jan 27;7(1):70-7. doi: 10.4254/wjh.v7.i1.70.

Cyclic adenosine monophosphate response element-binding protein transcriptionally regulates CHCHD2 associated with the molecular pathogenesis of hepatocellular carcinoma. Song R1, Yang B2, Gao X1, et al. Mol Med Rep. 2015 Jan 26. doi: 10.3892/mmr.2015.3256. [Epub ahead of print]

Caring Ambassadors Program, Inc. | P.O. Box 1748 | Oregon City, OR 97045 | 503-632-9032 | 503-632-9038 (Fax)